Is Metformin a GLP‑1? Metformin vs Ozempic, Wegovy and Mounjaro

No. Metformin belongs to a different drug class and does not act on the GLP-1 receptor.1 Its label says metformin decreases glucose production in the liver, decreases glucose absorption from the intestine and improves insulin sensitivity by increasing glucose uptake.1 The label also states that its mechanisms differ from other classes of oral diabetes drugs.1

Only in its main purpose: both are approved to improve blood sugar control in adults with type 2 diabetes.1,2 Ozempic is a GLP-1 receptor agonist injected once a week.2 Metformin is a tablet taken by mouth, and with metformin therapy insulin secretion stays unchanged.1

No. Semaglutide is the active ingredient in Ozempic, Wegovy and Rybelsus; metformin is a separate molecule, metformin hydrochloride.2,3,1 For the semaglutide family, see what is Ozempic.

Of these four, only Wegovy is FDA-approved for weight reduction.3 For how the semaglutide brands differ from each other, see Ozempic vs Wegovy. Metformin's label lists one use: improving glycemic control in adults and children with type 2 diabetes.1

Ozempic and metformin both treat type 2 diabetes, but Ozempic is a weekly GLP-1 injection with heart and kidney indications, while metformin is a daily tablet approved for blood sugar control.2,1 Ozempic is also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and heart disease, and to reduce kidney decline in those with chronic kidney disease.2

On weight, the two differ sharply. In a 29-week placebo-controlled study in the Glucophage label, weight changed by −1.4 lb on metformin and −2.4 lb on placebo, a difference that was not statistically significant.1 The label says weight on metformin "tended to remain stable or even decrease somewhat."1 In a 56-week Ozempic trial in which 94% of patients also took metformin, average weight fell 4.2 kg on Ozempic 0.5 mg and 5.5 kg on Ozempic 1 mg, against 1.7 kg on sitagliptin.2

Semaglutide produces much larger average weight loss than metformin in trials, and only semaglutide (as Wegovy) is approved for weight reduction.3,1

• Wegovy 2.4 mg, adults without diabetes: 14.9% average loss at 68 weeks, against 2.4% on placebo.3
• Wegovy 2.4 mg, adults with type 2 diabetes: 9.6% at 68 weeks, against 3.4% on placebo.3
• Metformin, Diabetes Prevention Program: after 1 year, 28.5% of the metformin group had lost at least 5% of body weight, against 13.4% on placebo.6

For comparison, 83.5% of adults on Wegovy 2.4 mg in the main weight trial lost at least 5%.3 The studies used different populations and lengths, so the numbers show scale rather than a head-to-head result.

Metformin's long-term record is real. In the Diabetes Prevention Program, metformin cut new cases of type 2 diabetes by 31% against placebo over an average of 2.8 years, while an intensive lifestyle program cut them by 58%.5 Among people who lost at least 5% in the first year, those originally on metformin kept off an average of 6.2% between years 6 and 15.6

Wegovy is approved for long-term weight reduction, cardiovascular risk reduction and MASH; metformin is approved only for type 2 diabetes.3,1 See how long Wegovy takes to work and Wegovy cost.

Mounjaro (tirzepatide) is a weekly GIP and GLP-1 injection for type 2 diabetes, and its main trials added it on top of metformin rather than replacing it.4 In SURPASS-2, adults already on metformin who added Mounjaro lost 7.6 kg at 5 mg, 9.3 kg at 10 mg and 11.2 kg at 15 mg over 40 weeks, against 5.7 kg with semaglutide 1 mg.4 HbA1c fell by 2.0 to 2.3 points on Mounjaro, against 1.9 on semaglutide.4 See Mounjaro dosage and Mounjaro vs Ozempic.

Yes, the combination is common: Ozempic, Wegovy and Mounjaro were all studied in people already taking metformin, and their labels do not call for a metformin dose change.2,3,4 The Ozempic label lists metformin as needing no dose adjustment when given with semaglutide.2 The Wegovy label reports no clinically significant change in metformin levels with semaglutide.3

The labels' low-blood-sugar warnings are about insulin and sulfonylureas, not metformin.2,4 Metformin alone does not usually cause hypoglycemia, though the risk rises when it is combined with sulfonylureas or insulin.1

Two practical cautions come from the labels:

• Stomach side effects can stack. Diarrhea affected 53.2% of patients on metformin monotherapy, against 11.7% on placebo, and nausea and diarrhea are among the most common GLP-1 side effects.1,3
• Dehydration matters. The metformin Medication Guide tells patients to contact their doctor if they have severe vomiting, diarrhea or fever, because dehydration may mean pausing metformin.1

Only a prescriber can decide whether to combine, continue or stop either drug.

Both cause mainly gastrointestinal side effects, but their serious risks differ.1,3 Metformin carries a boxed warning for lactic acidosis, a rare but potentially fatal buildup of lactate, with higher risk in kidney impairment.1 Its label also notes falls in vitamin B12 levels in some patients.1 GLP-1 drugs carry a boxed warning about thyroid C-cell tumors seen in rodents, plus warnings on pancreatitis and gallbladder disease.3 Details are in Ozempic side effects and Mounjaro side effects.

Which is better, Ozempic or metformin? Neither is better for everyone. Ozempic lowered weight more in trials and has heart and kidney indications, while metformin is an oral tablet with a long track record.2,1 Your prescriber will weigh your blood sugar, other conditions and cost.

Can you take Wegovy and metformin together? Wegovy's weight trials in adults with type 2 diabetes allowed metformin, and the label reports no clinically significant interaction.3

Can you take Mounjaro and metformin together? Yes. In SURPASS-2, Mounjaro was added to stable metformin doses.4

Is metformin approved for weight loss? No. Its label covers glycemic control in type 2 diabetes only.1

Does metformin work like a GLP-1 on appetite? Its label describes effects on the liver, gut glucose absorption and insulin sensitivity, not on GLP-1 receptors.1 For how GLP-1 drugs act on appetite, see what is GLP-1.

If you are comparing GLP-1 options for weight loss rather than diabetes, see our best GLP-1 programs and the Ozempic cost and Mounjaro cost guides, or check who qualifies for a GLP-1.

This article is for information only and is not medical advice. Do not start, stop or combine metformin or any GLP-1 medication without your prescriber.